Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus Ibrutinib and Rituximab vs Bendamustine plus Ibrutinib and Rituximab in treatment-naive mantle cell lymphoma not eligible for high-dose therapy
2020-002935-30Phase 2Active
- Sponsor
- University Medical Center Mainz
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of venetoclax, ibrutinib, rituximab and bendamustine in mantle cell lymphoma (MCL) (2 arms), sponsored by University Medical Center Mainz. Primary endpoint: Primary efficacy endpoint. Started Nov 2022; status: active.
02
Drugs
venetoclaxibrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2020-002935-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002935-30.